Cargando…
Corrigendum to “Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost” [Biochem. Pharmacol. 178 (2020) 114057]
Autores principales: | Mohammed El Tabaa, Manar, Mohammed El Tabaa, Maram |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533109/ https://www.ncbi.nlm.nih.gov/pubmed/33027739 http://dx.doi.org/10.1016/j.bcp.2020.114249 |
Ejemplares similares
-
Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost
por: Mohammed El Tabaa, Manar, et al.
Publicado: (2020) -
New putative insights into neprilysin (NEP)-dependent pharmacotherapeutic role of roflumilast in treating COVID-19
por: El Tabaa, Manar Mohammed, et al.
Publicado: (2020) -
Corrigendum to “The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors” [Pharmacol. Res. 147 (2019) 104392]
por: Bechman, Katie, et al.
Publicado: (2020) -
Silymarin constrains diacetyl-prompted oxidative stress and neuroinflammation in rats: involvements of Dyn/GDNF and MAPK signaling pathway
por: Tabaa, Manar Mohammed El, et al.
Publicado: (2022) -
Corrigendum to “Genetic epidemiology of motor neuron disease-associated variants in the Scottish population.” [Neurobiol. Aging 51 (2017) 178.e11–178.e20]
por: Black, Holly A., et al.
Publicado: (2017)